JP2021531255A5 - - Google Patents
Info
- Publication number
- JP2021531255A5 JP2021531255A5 JP2021500442A JP2021500442A JP2021531255A5 JP 2021531255 A5 JP2021531255 A5 JP 2021531255A5 JP 2021500442 A JP2021500442 A JP 2021500442A JP 2021500442 A JP2021500442 A JP 2021500442A JP 2021531255 A5 JP2021531255 A5 JP 2021531255A5
- Authority
- JP
- Japan
- Prior art keywords
- antigen
- binding fragment
- monoclonal antibody
- antibody
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862702143P | 2018-07-23 | 2018-07-23 | |
| US62/702,143 | 2018-07-23 | ||
| PCT/US2019/043108 WO2020023548A1 (en) | 2018-07-23 | 2019-07-23 | Antibodies targeting a complex comprising non-classical hla-i and neoantigen and their methods of use |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021531255A JP2021531255A (ja) | 2021-11-18 |
| JP2021531255A5 true JP2021531255A5 (enExample) | 2022-08-01 |
Family
ID=69181238
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021500442A Pending JP2021531255A (ja) | 2018-07-23 | 2019-07-23 | 非古典的ｈｌａ−ｉおよびネオアンチゲンを含む複合体を標的とする抗体、およびその使用方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20210253713A1 (enExample) |
| EP (1) | EP3827021A4 (enExample) |
| JP (1) | JP2021531255A (enExample) |
| AU (1) | AU2019309948A1 (enExample) |
| CA (1) | CA3107001A1 (enExample) |
| WO (1) | WO2020023548A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11118215B2 (en) | 2003-09-18 | 2021-09-14 | Nuevolution A/S | Method for obtaining structural information concerning an encoded molecule and method for selecting compounds |
| CA3183756A1 (en) | 2020-05-19 | 2021-11-25 | Amgen Inc. | Mageb2 binding constructs |
| US10981997B1 (en) | 2020-06-01 | 2021-04-20 | Abexxa Biologics, Inc. | Antibodies targeting a complex comprising non-classical HLA-I and neoantigen and their methods of use |
| US10981996B1 (en) * | 2020-06-01 | 2021-04-20 | Abexxa Biologics, Inc. | Antibodies targeting a complex comprising non-classical HLA-I and neoantigen and their methods of use |
| US11976120B2 (en) * | 2020-06-01 | 2024-05-07 | Boehringer Ingelheim International Gmbh | Antibodies targeting a complex comprising non-classical HLA-I and neoantigen and their methods of use |
| US20250051454A1 (en) * | 2020-09-15 | 2025-02-13 | Duke University | Antibodies that target hla-e-host peptide complexes and uses thereof |
| EP4388012A4 (en) * | 2021-08-20 | 2025-09-17 | Univ Duke | ANTIBODIES TARGETING HLA-E-HOST PEPTIDE COMPLEXES AND THEIR USES |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1790664A1 (en) * | 2005-11-24 | 2007-05-30 | Ganymed Pharmaceuticals AG | Monoclonal antibodies against claudin-18 for treatment of cancer |
| PE20090321A1 (es) * | 2007-06-04 | 2009-04-20 | Genentech Inc | Anticuerpos anti-notch1 nrr, metodo de preparacion y composicion farmaceutica |
| EP2699603B1 (en) * | 2011-04-19 | 2016-03-02 | The United States of America As Represented by the Secretary Department of Health and Human Services | Human monoclonal antibodies specific for glypican-3 and use thereof |
| US10656156B2 (en) * | 2012-07-05 | 2020-05-19 | Mepur Ravindranath | Diagnostic and therapeutic potential of HLA-E monospecific monoclonal IgG antibodies directed against tumor cell surface and soluble HLA-E |
| US10329348B2 (en) * | 2014-10-23 | 2019-06-25 | Innate Pharma | Treatment of cancers using anti-NKG2A agents |
| EP3475706B1 (en) * | 2016-06-27 | 2021-08-11 | Juno Therapeutics, Inc. | Mhc-e restricted epitopes, binding molecules and related methods and uses |
| EP3573997A4 (en) * | 2017-01-24 | 2020-12-09 | Abexxa Biologics, Inc. | METHODS AND COMPOSITIONS INTENDED TO TARGE A COMPLEX INCLUDING A NON-CLASSIC HLA-I AND A NEO-ANTIGEN IN THE TREATMENT OF CANCER |
| US10981997B1 (en) * | 2020-06-01 | 2021-04-20 | Abexxa Biologics, Inc. | Antibodies targeting a complex comprising non-classical HLA-I and neoantigen and their methods of use |
| US10981996B1 (en) * | 2020-06-01 | 2021-04-20 | Abexxa Biologics, Inc. | Antibodies targeting a complex comprising non-classical HLA-I and neoantigen and their methods of use |
| US11976120B2 (en) * | 2020-06-01 | 2024-05-07 | Boehringer Ingelheim International Gmbh | Antibodies targeting a complex comprising non-classical HLA-I and neoantigen and their methods of use |
-
2019
- 2019-07-23 US US17/250,443 patent/US20210253713A1/en not_active Abandoned
- 2019-07-23 WO PCT/US2019/043108 patent/WO2020023548A1/en not_active Ceased
- 2019-07-23 CA CA3107001A patent/CA3107001A1/en active Pending
- 2019-07-23 AU AU2019309948A patent/AU2019309948A1/en not_active Abandoned
- 2019-07-23 EP EP19841883.2A patent/EP3827021A4/en not_active Withdrawn
- 2019-07-23 JP JP2021500442A patent/JP2021531255A/ja active Pending